SREBF1 and non-small cell lung carcinoma: In summary, our data initially exhibit the MAPK/SREBP1 pathway were responsible for gefitinib resistance in NSCLC cells and draw a conclusion that the combined treatment of SFI augmented gefitinib's anti-proliferation and pro-apoptosis potential in NSCLC gefitinib resistant cells through regulating MAPK/SREBP1 pathway.